凯普生物(300639) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 reached ¥1,510,718,034.62, representing a 147.87% increase compared to ¥609,471,858.80 in the same period last year[4] - Net profit attributable to shareholders was ¥499,725,567.45, a 190.64% increase from ¥171,939,617.11 year-on-year[4] - The net profit excluding non-recurring gains and losses was ¥491,776,771.95, up 201.55% from ¥163,082,987.01 in the previous year[4] - Basic earnings per share increased to ¥1.72, a rise of 196.55% from ¥0.58 in the previous year[4] - Total operating revenue for the current period reached ¥1,510,718,034.62, a significant increase from ¥609,471,858.80 in the previous period, representing a growth of approximately 147.5%[42] - Net profit for the current period was ¥551,717,509.33, compared to ¥188,197,415.46 in the previous period, reflecting an increase of approximately 194.0%[43] - Basic and diluted earnings per share were both ¥1.72, up from ¥0.58 in the previous period, marking an increase of approximately 196.6%[44] Cash Flow and Investments - The net cash flow from operating activities was ¥119,282,306.10, a significant improvement of 339.07% compared to a negative cash flow of ¥49,894,766.64 in the same period last year[4] - Cash flow from operating activities generated a net amount of ¥119,282,306.10, a turnaround from a negative cash flow of ¥49,894,766.64 in the previous period[45] - Cash received from investment decreased significantly by 58.68% to ¥611,800,000.00 from ¥1,480,606,837.73, mainly due to a reduction in the recovery of matured financial products[16] - The company invested ¥497,600,000.00 in cash during the period, a decrease of 63.01% compared to ¥1,345,200,000.00, reflecting reduced investment in financial products[16] - Investment activities resulted in a net cash outflow of ¥-52,701,101.43, contrasting with a net inflow of ¥42,290,234.91 in the previous period[46] Assets and Liabilities - Total assets at the end of Q1 2022 were ¥5,137,517,950.16, reflecting a 21.41% increase from ¥4,231,385,338.40 at the end of the previous year[4] - The total assets of the company reached ¥5.14 billion, up from ¥4.23 billion, reflecting a growth of about 21.5%[40] - The company's total liabilities increased to ¥1.11 billion from ¥756.37 million, an increase of approximately 46.7%[40] - The company's retained earnings grew to ¥2.08 billion from ¥1.58 billion, an increase of about 31.6%[40] Operational Highlights - Revenue from self-produced products was RMB 274.72 million, an increase of 47.17% year-on-year, while revenue from purchased products decreased by 25.49% to RMB 40.18 million[24] - The company has established 37 third-party medical laboratories across key provinces and cities, with 30 of them operational, contributing to a medical testing service revenue of RMB 1,195.82 million, a growth of 224.17%[25] - The company won a bid to establish a third-party medical testing laboratory in Foshan, which will have a daily testing capacity of 10,000 samples under normal conditions and 100,000 during emergencies[26] - The company received a medical device production license for its wholly-owned subsidiary, enhancing its operational capabilities[36] - The company is conducting Phase II clinical trials for its newly developed drug "Chloroquine Phosphate Gel," which is currently under evaluation for safety and efficacy[33] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 37,877, with no preferred shareholders[18] - The largest shareholder, Hong Kong Science and Technology Venture Capital Co., Ltd., holds 29.22% of the shares, totaling 85,865,919 shares[18] - The company’s repurchase account held 2,649,200 shares, representing 0.90% of total shares, ranking ninth among all shareholders[20] Research and Development - The company invested RMB 32.06 million in R&D, marking a 10.31% increase compared to the previous year[24] - The company obtained 9 new patents during the reporting period, including 4 invention patents and 1 Australian invention patent[33] Tax and Expenses - The income tax expense for Q1 2022 was ¥119,285,611.97, a 208.98% increase from ¥38,606,510.08 in the same period last year, driven by higher profitability[13] - Cash paid to employees increased by 71.51% to ¥134,265,895.46 from ¥78,283,851.82, mainly due to higher salaries and bonuses[16] - Cash paid for various taxes rose by 49.04% to ¥53,838,498.43 from ¥36,124,476.59, attributed to increased VAT and income tax payments[16] Currency Exchange Impact - The company experienced a significant currency exchange impact, with cash and cash equivalents affected by ¥-5,243,050.81, a 626.26% increase in negative impact compared to ¥-721,923.35 in the previous year, due to substantial appreciation of the RMB[16] - The company experienced a foreign exchange loss of ¥-5,243,050.81, compared to a loss of ¥-721,923.35 in the previous period, indicating increased volatility in currency exchange rates[46]